Recurrent or Metastatic Cervical Cancer

Explore clinical trials studying Recurrent or Metastatic Cervical Cancer. Study availability and eligibility vary by location and protocol.

7 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Recurrent or Metastatic Cervical Cancer trial results

Recruiting

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

NCT07051486

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Fujian Cancer Hospital Fuzhou, Fujian, China

Shandong University Qilu Hospital Jinan, Shandong, China

View Trial Details

Recruiting

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

NCT06859775

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China

View Trial Details

Not Yet Recruiting

TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer

NCT07652983

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

NCT07542717

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06155422

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Not specified

View Trial Details

Completed

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

NCT04680988

Conditions: Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +15 more
Locations: Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China

View Trial Details

Completed

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

NCT04868708

Conditions: Diabetes Mellitus, Insulin-Dependent, 12, Disease Attributes, Female Urogenital Diseases, +16 more
Locations: Hunan Cancer Hospital Changsha, Hunan, China

Zhejiang Cancer Hospital Hangzhou, Zhejiang, China

View Trial Details

Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer trial results

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Related conditions